Applicant: Duchon et al. Docket No.: 20144-500 Serial No.: 10/726.433 Group Art Unit: 3743

AMENDMENTS TO THE CLAIMS

PATENT

Claims 5, 40, 54, 56, 59 and 66 were previously canceled.

Please cancel claims 4, 14, 22, 31, 39, 40, 47, 55, and 63.

Please amend claims 1, 3, 10, 11, 12, 15, 18, 20, 21, 28, 30, 36, 37, 38, 44, 45, 49, 51, 53, and 61 as set forth below.

LISTING OF CLAIMS

1 (Currently Amended) A method of changing a gynecological condition of a female comprising:

evaluating the condition of a uterus of said female;

introducing a presterilized implant into said uterus with a delivery tool;

contacting said implant with uterine tissue so as to induce a tissue response in said uterus:

detaching said implant from said delivery tool:

maintaining contact between said implant and said uterine tissue at least until walls of said uterus adhere together and cause a changed gynecological condition in said female, wherein the contact between said implant and said uterine tissue is maintained at least until menorrhagia has been substantially eliminated in said female.

- 2 (Original) A method according to claim 1, wherein the contact between said implant and said uterine tissue is maintained at least until adhesions are formed in said uterus.
- 3. (Currently Amended) A method according to claim 1, wherein the contact between said implant and said uterine tissue is further maintained at least until contraception in said uterus is achieved.

 Applicant:
 Duchon et al.
 PATENT

 Serial No.: 10/726,433
 Docket No.: 20144-500

 Group Art Unit: 3743
 Docket No.: 20144-500

(Canceled)

(Canceled)

- (Original) A method according to claim 1, wherein said presterilized implant is coated with an adhesion inducing substance.
- (Previously Presented) A method according to claim 1, wherein said presterilized implant is coated with a biologic coating prior to introducing said implant into said uterus.
- 8. (Original) A method according to claim 1, wherein said presterilized implant is formulated at least in part from polyester prior to its introduction into said uterus.
- 9. (Previously Presented) A method according to claim 1, wherein said presterilized implant is introduced through a delivery tool that comprises a catheter.
- 10. (Currently Amended) An implant for changing the gynecological state of a female comprising:

a self-contained presterilized substance disconnectable from a delivery tool;

said self-contained substance configured for causing a tissue response in uterine tissue; and.

said self-contained substance sized and shaped for sufficiently contacting uterine tissue such that uterine walls of said uterine tissue adhere together and thereby cause a gynecological change in said female, wherein said self-contained presterilized substance includes a frame, at least a portion of which is covered by a mesh material.

11. (Currently Amended) An implant according to claim 10, wherein said self-contained presterilized substance is a substantially covered by said mesh material.

Group Art Unit: 3743

12. (Currently Amended) An implant according to claim 10, wherein said selfeentained presterilized-substance mesh material is a polyester material.

13. (Previously Presented) An implant according to claim 10, wherein said self-

contained presterilized substance is coated with an adhesion inducing substance.

14. (canceled)

15. (Currently Amended) An implant according to claim 14 10, wherein said mesh

material is comprised substantially of polyester.

16. (Original) An implant according to claim 15, wherein said frame includes a

plurality of linear extensions, at least two of such extensions sized and shaped to

extend across a uterine wall.

17. (Original) An implant according to claim 16, wherein said at least two extensions

are movable between a collapsible and a deployed position.

(Currently Amended) An implant according to claim 10, wherein said substance

is sized and shaped so as to eliminate menorragia menorrhagia.

19. (Previously Presented) An implant according to claim 10, wherein said substance

is sized and shaped so as to further cause contraception in said uterus.

20. (Currently Amended) A method of changing a gynecological condition of a female

comprisina:

evaluating the condition of a uterus of said female:

introducing a presterilized implant into said uterus;

Page 4 of 14

12292 1.DOC

Applicant: Duchon et al. Docket No.: 20144-500 Serial No.: 10/726,433

Group Art Unit: 3743

contacting said implant with uterine tissue so as to induce a tissue response in

maintaining contact between said implant and said uterine tissue at least until

adhesions are formed in said uterus, said adhesions causing a changed gynecological condition in said female, wherein the changed gynecological condition is substantial

elimination of menorrhagia.

21. (Currently Amended) A method according to claim 20, wherein the changed

avnecological condition is also includes contraception.

22. (Canceled)

said uterus:

23. (Previously Presented) A method according to claim 20, wherein formation of

said adhesions includes causing walls of said uterus to adhere together.

24 (Previously Presented) A method according to claim 20, wherein said

presterilized implant is coated with an adhesion inducing substance.

25. (Previously Presented) A method according to claim 20, wherein said

presterilized implant is coated with a biologic coating prior to introducing said implant

into said uterus.

26 (Previously Presented) A method according to claim 20, wherein said

presterilized implant is formulated at least in part from polyester prior to its introduction

into said uterus.

27. (Previously Presented) A method according to claim 20, wherein said

presterilized implant is introduced through a catheter.

Page 5 of 14

12292_1.DOC

PATENT

Group Art Unit: 3743

28. (Currently Amended) A method of changing a gynecological condition of a female

comprising:

evaluating the condition of a uterus of said female;

introducing a presterilized implant into said uterus;

contacting said implant with uterine tissue so as to induce a tissue response in

said uterus;

maintaining contact between said implant and said uterine tissue at least until

walls of said uterus adhere together, said adhering of said walls causing a changed

gynecological condition in said female, wherein the changed gynecological condition

includes the substantial elimination of menorrhagia.

29. (Previously Presented) A method according to claim 28, wherein the adhering of

said walls includes the formation of adhesions in said uterus.

30. (Currently Amended) A method according to claim 28, wherein the changed

gynecological condition <u>further</u> includes contraception.

(Canceled)

32. (Previously Presented) A method according to claim 28, wherein said

presterilized implant is coated with an adhesion inducing substance.

33. (Previously Presented) A method according to claim 28, wherein said

presterilized implant is coated with a biologic coating prior to introducing said implant

into said uterus.

Page 6 of 14

12292 1.DOC

Group Art Unit: 3743

34. (Previously Presented) A method according to claim 28, wherein said presterilized implant is formulated at least in part from polyester prior to its introduction

into said uterus

35. (Previously Presented) A method according to claim 28, wherein said

presterilized implant is introduced through a catheter.

36. (Currently Amended) A method of changing a gynecological condition of a female

comprisina:

evaluating the condition of a uterus of said female:

formulating a presterilized implant at least in part from polyester:

introducing said presterilized implant into said uterus;

contacting said implant with uterine tissue so as to induce a tissue response in

said uterus;

maintaining contact between said implant and said uterine tissue at least until

walls of said uterus adhere together and cause a changed gynecological condition in

said female, wherein the contact between said implant and said uterine tissue is maintained at least until menorrhagia has been substantially eliminated in said female.

37. (Currently Amended) A method according to claim 36, wherein the contact

between said implant and said uterine tissue is <u>further</u> maintained at least until

adhesions are formed in said uterus.

38. (Previously Presented) A method according to claim 36, wherein the contact

between said implant and said uterine tissue is further maintained at least until

contraception in said uterus is achieved.

39. (Canceled)

Serial No.: 10/726,433 Group Art Unit: 3743

40. (Canceled)

41. (Previously Presented) A method according to claim 36, wherein said

presterilized implant is coated with an adhesion inducing substance.

42. (Previously Presented) A method according to claim 36, wherein said

presterilized implant is coated with a biologic coating prior to introducing said implant

into said uterus.

43. (Previously Presented) A method according to claim 36, wherein said

presterilized implant is introduced through a catheter.

44. (Currently Amended) An implant for changing the gynecological state of a female

comprising:

a presterilized substance in the form of a mesh material;

said substance configured for causing a tissue response in uterine tissue; and,

said substance sized and shaped for sufficiently contacting uterine tissue such

that walls of said uterine tissue adhere together and thereby cause a gynecological change in said female, wherein said presterilized substance includes a frame, at least a

portion of which is covered by said mesh material.

45. (Currently Amended) An implant according to claim 44, wherein said presterilized

substance mesh material is a polyester mesh material.

46. (Previously Presented) An implant according to claim 44, wherein said

presterilized substance is coated with an adhesion inducing substance.

47. (Canceled)

Group Art Unit: 3743

48. (Previously Presented) An implant according to claim 44, wherein said mesh

material is comprised substantially of polyester.

49. (Currently Amended) An implant according to claim 47 44, wherein said frame

includes a plurality of linear extensions, at least two of such extensions sized and

shaped to extend across a uterine wall.

50. (Previously Presented) An implant according to claim 49, wherein said at least

two extensions are movable between a collapsible and a deployed position.

51. (Currently Amended) An implant according to claim 44, wherein said presterilized

substance is sized and shaped so as to further cause the elimination of menorragia

menorrhagia.

52. (Previously presented) An implant according to claim 44, wherein said

presterilized substance is sized and shaped so as to further cause contraception in said

uterus.

53. (Currently Amended) An implant for changing the gynecological state of a female

comprising:

a presterilized substance comprised of a frame at least partially covered by a

polyester mesh material:

said substance configured for causing a tissue response in uterine tissue; and,

said substance sized and shaped for sufficiently contacting uterine tissue such that menorrhagia menorrhagia is eliminated in said female, wherein said presterilized

substance is coated with an adhesion inducing substance.

54. (Canceled)

Applicant: Duchon et al. PATENT Docket No.: 20144-500 Serial No.: 10/726,433

Group Art Unit: 3743

55. (Canceled)

56. (Canceled)

57 (Previously Presented) An implant according to claim 53, wherein said frame includes a plurality of linear extensions, at least two of such extensions sized and shaped to extend across a uterine wall.

58. (Previously Presented) An implant according to claim 57, wherein said at least two extensions are movable between a collapsible and a deployed position.

59 (Canceled)

60. (Previously Presented) An implant according to claim 53, wherein said substance is sized and shaped so as to further cause contraception in said uterus.

61. (Currently Amended) An implant for changing the gynecological state of a female comprising:

a presterilized substance having a frame, at least a portion of which is covered by a mesh material.:

said substance configured for causing a tissue response in uterine tissue; and,

said substance sized and shaped for sufficiently contacting uterine tissue such that menorragia menorrhagia is eliminated in said female, wherein said presterilized substance is coated with an adhesion inducing substance.

62. (Previously Presented) An implant according to claim 61, wherein said mesh material is a polyester material.

63. (Canceled)

Serial No.: 10/726,433 Docket No.: 20144-5 Group Art Unit: 3743

64. (Previously Presented) An implant according to claim 61, wherein said frame includes a plurality of linear extensions, at least two of such extensions sized and shaped to extend across a uterine wall.

- 65. (Previously Presented) An implant according to claim 64, wherein said at least two extensions are movable between a collapsible and a deployed position.
- 66. (Canceled)
- 67. (Previously Presented) An implant according to claim 61, wherein said substance is sized and shaped so as to further cause contraception in said uterus.